These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23571389)

  • 21. Addition of incretin therapy to metformin in type 2 diabetes.
    Scheen AJ; Radermecker RP
    Lancet; 2010 Apr; 375(9724):1410-2. PubMed ID: 20417840
    [No Abstract]   [Full Text] [Related]  

  • 22. [Liraglutide in the treatment of diabetes type 2].
    Novak B; Metelko Z
    Lijec Vjesn; 2011; 133(7-8):269-76. PubMed ID: 22165195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New treatments for type 2 diabetes in the UK - an evolving landscape.
    Barnett AH
    Prim Care Diabetes; 2011 Apr; 5(1):1-7. PubMed ID: 20934929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in incretin-based therapies.
    Russell-Jones D; Gough S
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Glucagon-like peptide-1 based therapy for type 2 diabetes].
    Yu BS
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):669-71. PubMed ID: 17217659
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of glucagon-like peptide-1 on endothelial function.
    Sjöholm A
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What's new in diabetes: incretins and C-peptide.
    Marks V
    Med Princ Pract; 2011; 20(2):101-2. PubMed ID: 21252561
    [No Abstract]   [Full Text] [Related]  

  • 30. New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists.
    George C; Byun A; Howard-Thompson A
    Am J Med; 2018 Nov; 131(11):1304-1306. PubMed ID: 29969616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Albiglutide approved for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2014 Jun; 71(11):888. PubMed ID: 24830988
    [No Abstract]   [Full Text] [Related]  

  • 32. GLP-1 receptor agonists for type 2 diabetes.
    De Block CE; Van Gaal LF
    Lancet; 2009 Jul; 374(9683):4-6. PubMed ID: 19515414
    [No Abstract]   [Full Text] [Related]  

  • 33. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycemic control impact on body weight potential to reduce cardiovascular risk: glucagon-like peptide 1 agonists.
    Sesti G
    Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S272-5. PubMed ID: 21525467
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiovascular effects of incretins in diabetes.
    Advani A; Bugyei-Twum A; Connelly KA
    Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incretins: the novel therapy of type 2 diabetes.
    Thongtang N; Sriwijitkamol A
    J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
    Gupta A; Jelinek HF; Al-Aubaidy H
    Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon-like peptide-1 and diabetes 2012.
    Monami M; Di Pasquale G; Rowzee A; Rotella CM; Mannucci E
    Exp Diabetes Res; 2012; 2012():768760. PubMed ID: 23431286
    [No Abstract]   [Full Text] [Related]  

  • 39. Should we be concerned about thyroid cancer in patients taking glucagon-like peptide 1 receptor agonists?
    Kannan S; Nasr C
    Cleve Clin J Med; 2015 Mar; 82(3):142-4. PubMed ID: 25932736
    [No Abstract]   [Full Text] [Related]  

  • 40. [Antidiabetics and the incretin system].
    Høibraaten E; Folkersen J
    Tidsskr Nor Laegeforen; 2008 Sep; 128(17):1985. PubMed ID: 18787580
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.